Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 13/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5768503 | 1.00 | GRM6 (0.37) | GRM6ADORA1KEAP1NFE2L2KMT2A | |
| SCHEMBL5768500 | 1.00 | GRM6 (0.37) | GRM6ADORA1KEAP1NFE2L2KMT2A | |
| SCHEMBL7003545 | 0.89 | KEAP1 (0.40) | ADORA1KEAP1NFE2L2KMT2A | |
| SCHEMBL5766511 | 0.87 | GRM6 (0.41) | GRM6ADORA1KMT2AMEN1LMNA | |
| SCHEMBL5768050 | 0.87 | GRM6 (0.41) | GRM6ADORA1KMT2AMEN1LMNA | |
| SCHEMBL5770902 | 0.87 | GRM6 (0.41) | GRM6ADORA1KMT2AMEN1LMNA | |
| SCHEMBL7560915 | 0.87 | GRM6 (0.41) | GRM6ADORA1KMT2AMEN1LMNA | |
| SCHEMBL5766514 | 0.87 | GRM6 (0.41) | GRM6ADORA1KMT2AMEN1LMNA | |
| SCHEMBL5837554 | 0.84 | ADORA1 (0.40) | GRM6ADORA1KEAP1NFE2L2MAPT | |
| SCHEMBL5838427 | 0.82 | HTR1A (0.34) | GRM6ADORA1KEAP1NFE2L2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115624-B1 | Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48 | NOVO NORDISK A/S (DK) | 2006-10-03 | — | — | US | disclosed |
| EP-1301516-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK AS (DK) | 2006-03-22 | — | — | EP | disclosed |
| US-6613903-B2 | Such as 7-(benzoylamino-methyl)-2-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno(2,3 -c)pyridine-3-carboxylic acid for treatment of diabetes, insulin resistance, and obesity | NOVO NORDISK A/S (DK) | 2003-09-02 | — | — | US | disclosed |
| US-20020151561-A1 | Modulators of Protein Tyrosine Phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2002-10-17 | — | — | US | disclosed |
| US-20020099073-A1 | Modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2002-07-25 | — | — | US | disclosed |
| US-6410556-B1 | ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2002-06-25 | — | — | US | disclosed |
| EP-1214324-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001019830-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151561-A1 | Modulators of Protein Tyrosine Phosphatases (PTPases) | PTPRO, PTPN1, PTPRS | GRM6 2745/4885ADORA1 1290/4885KEAP1 2361/4885 |
| US-20020099073-A1 | Modulators of protein tyrosine phosphatases (PTPases) | PTPN1, PTPRO, PTPRS | GRM6 3132/4885ADORA1 1492/4885KEAP1 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.